The article outlines some of the Key Findings of the 2022 Index, with Jayasree sharing her insights on the progress made by the pharmaceutical industry in addressing access to medicine in low- and middle-income countries (LMICs). However, Jayasree emphasised that this progress largely overlooks sizeable populations in low-income countries.
“If we consistently see that the industry leaves low-income countries behind, then we're never going to solve the problem of access at scale,” she told the outlet.
Reuters also highlighted the fact that only five of the pharmaceutical companies in scope of the 2022 Index are targeting emerging infectious diseases other than COVID-19 – a key finding from the Index that indicates companies are not sufficiently targeting pathogens that could trigger the next pandemic our serious epidemic.
Read the full article on the Reuters website.